Rucaparib Camsylate
CAS 849217-64-7 4 FDA-DMF suppliersSmall Molecule
Overview
Rucaparib Camsylate is a small molecule inhibitor targeting the enzyme Poly (ADP-ribose) polymerase (PARP), used in the treatment of ovarian cancer. It works by interfering with DNA repair mechanisms, thus promoting cell death in cancer cells.
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Rucaparib Camsylate expires 16 Aug 2035 and exclusivity 17 Dec 2028. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyOvarian Cancer
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.